DA
ALNY icon

Duality Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Duality Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,197
Closed -$1.67M – 23
2024
Q1 		$1.67M Sell
11,197
-5,915
-35% -$987K 0.17% 218
2023
Q4 		$3.28M Buy
17,112
+7,682
+81% +$1.31M 0.35% 84
2023
Q3 		$1.67M Buy
9,430
+5,697
+153% +$1.09M 0.2% 183
2023
Q2 		$709K Buy
3,733
+1,682
+82% +$333K 0.09% 341
2023
Q1 		$411K Buy
+2,051
New +$431K 0.05% 444
2022
Q4 		– Sell
-16,926
Closed -$3.39M – 571
2022
Q3 		$3.39M Buy
16,926
+13,274
+363% +$2.53M 0.37% 77
2022
Q2 		$533K Sell
3,652
-1,819
-33% -$258K 0.05% 455
2022
Q1 		$893K Sell
5,471
-6,702
-55% -$1.02M 0.1% 352
2021
Q4 		$2.06M Sell
12,173
-4,631
-28% -$861K 0.22% 174
2021
Q3 		$3.17M Buy
+16,804
New +$3.15M 0.24% 164
2021
Q2 		– Sell
-12,039
Closed -$1.7M – 521
2021
Q1 		$1.7M Sell
12,039
-4,981
-29% -$750K 0.15% 249
2020
Q4 		$2.21M Buy
+17,020
New +$2.27M 0.16% 189

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Duality Advisers's ALNY Position: Q2 2024 in Review

Duality Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 11,197 shares — an estimated $1.67M sold.

Duality Advisers first reported a position in ALNY in Q4 2020 and held it in 12 quarters. The position peaked at $3.39M in Q3 2022. 522 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Duality Advisers reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 11,197 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $1.67M.
  • Duality Advisers first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 12 quarters.
  • Duality Advisers's Alnylam Pharmaceuticals position peaked at $3.39M in Q3 2022.
  • 522 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.